ICH E6(R3) draft Guideline reaches Step 2 of the ICH process [BE/BA News]

posted by SMA – Europe, 2023-05-24 10:37 (386 d 01:56 ago) – Posting: # 23565
Views: 1,657

The ICH E6(R3) draft Guideline on “Good Clinical Practice (GCP)” has reached Step 2 of the ICH process on 19 May 2023.
The E6(R3) draft Guideline and guidance for stakeholder public consultation comment collection are available for download on the E6(R3) page.
The guideline is composed of principles and annexes that expand on the principles with specific details for different types of clinical trials.
The guideline applies to interventional clinical trials of investigational products that are intended to be submitted to regulatory authorities and may also be applicable to other interventional clinical trials of investigational products that are not intended to support marketing authorisation applications in accordance with local requirements.
Annex 1 which is included in this Step 2 document is intended to provide information on how the concepts can be appropriately applied to clinical trials.
Work on Annex 2, regarding additional considerations for interventional clinical trials, has just been initiated, with an Annex 2 Concept Paper approved in May 2023 by the ICH Management Committee.

Regional consultations will follow for those interested in providing comments.

Complete thread:

UA Flag
 Admin contact
23,056 posts in 4,840 threads, 1,641 registered users;
87 visitors (0 registered, 87 guests [including 9 identified bots]).
Forum time: 12:34 CEST (Europe/Vienna)

Everything is trivial, if you know the answer.    Thomas Jaki

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz